

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/E3FEE7A99F83EN.html>

Date: April 2022

Pages: 119

Price: US\$ 3,500.00 (Single User License)

ID: E3FEE7A99F83EN

Abstracts

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Exportin 1 - Drugs In Development, 2022'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The report 'Exportin 1 - Drugs In Development, 2022' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule

type; that are being developed by Companies/Universities.

It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2 and 2 respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease and Metabolic Disorders which include indications Diffuse Large B-Cell Lymphoma, Solid Tumor, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Endometrial Cancer, Liposarcoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma, Amyloidosis, Amyotrophic Lateral Sclerosis, Anaplastic Astrocytoma, B-Cell Non-Hodgkin Lymphoma, Bone Sarcoma, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Coronavirus Disease 2019 (COVID-19), Cytomegalovirus (HHV-5) Infections, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fallopian Tube Cancer, Follicular Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumor, Hematological Tumor, Hepatocellular Carcinoma, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Nasopharyngeal Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Transplant Lymphoproliferative Disorder, Primary Mediastinal B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Respiratory Syncytial

Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Spinal Cord Injury, Synovial Sarcoma, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Unspecified Influenza Virus Infections, Urinary Tract Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Companies Involved in Therapeutics Development

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones

Featured News & Press Releases

Apr 06, 2022: Antengene's pivotal "MARCH" study to evaluate selinexor (ATG-010) in relapsed or refractory multiple myeloma published in BMC Medicine

Mar 29, 2022: Antengene announces IND approval in China for a phase II study of Eltanexor (ATG-016) in patients with High-Risk Myelodysplastic Syndrome

Mar 16, 2022: Karyopharm announces upcoming presentations of phase 3 SIENDO study of selinexor in patients with advanced or recurrent endometrial cancer

Mar 09, 2022: Antengene announces XPOVIO approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma

Mar 01, 2022: Antengene announces XPOVIO regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications

Mar 01, 2022: Karyopharm provides U.S. regulatory update on Selinexor in advanced or recurrent Endometrial Cancer

Feb 08, 2022: Karyopharm announces Phase 3 SIENDO study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer

Jan 24, 2022: Karyopharm receives orphan drug designation from FDA for eltanexor for the treatment of myelodysplastic syndromes

Dec 29, 2021: Antengene announces first patient dosed in REACH study of ATG-016 for the treatment of advanced solid tumors

Dec 18, 2021: Antengene announces NDA approval by NMPA for XPOVIO, China's first XPO1 inhibitor, for the treatment of adults with relapsed or refractory multiple myeloma

Dec 14, 2021: Antengene presents results of phase 1b TOUCH trial of Selinexor for the treatment of T and NK-Cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

Dec 11, 2021: Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition

Dec 06, 2021: Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician's choice in previously treated myelofibrosis

Dec 02, 2021: Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer

Nov 18, 2021: Antengene announces IND approval in China for a phase I/II Study of Selinexor (ATG-010) in patients with non-Hodgkin lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Biogen Inc, 2022
Pipeline by CanBas Co Ltd, 2022
Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Pipeline by Karyopharm Therapeutics Inc, 2022
Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
Pipeline by Wigen Biomedicine Technology (Shanghai) Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E3FEE7A99F83EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E3FEE7A99F83EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970